| SYMBOL + | COMPANY + | RSI = | PERF (WTD) = | | --- | --- | --- | --- | | NFLX | Netflix | 74.97 | 2,90 | | VRSN | VeriSign | 74.06 | 2.53 | | CAH | Cardinal Health | 74.01 | 5.79 | | PWR | Quanta Services | 72.83 | 12.04 | | MSFT | Microsoft | 72.78 | 8.56 | | PLTR | Palantir Technologies | 71.91 | 3.03 | | APH | Amphenol | 71.52 | 3.67 | | HWM | Howmet Aerospace | 71.43 | 9.04 | | TT | Trane Technologies | 70.96 | 12.83 | | IDXX | IDEXX Laboratories | 70.01 | 7.76 | 微软（MSFT）本周成为最被高估的股票之一，其RSI达到72.78。LSE ...

Market Overview - The stock market experienced significant volatility due to President Trump's latest tariff announcements, with investors awaiting potential agreements between the U.S. and trade partners [1] - Major indices rebounded after an initial decline, with the S&P 500 rising over 4%, the Nasdaq Composite increasing nearly 7%, and the Dow Jones Industrial Average gaining over 2% [1] Company Performance - VeriSign's stock rose 8% on Friday, reaching a new intraday high, following a strong first-quarter revenue report and the announcement of a cash dividend of $0.77 per share [4] - Netflix's stock also reached a new intraday high, increasing over 13% for the week, driven by a 13% growth in first-quarter revenue attributed to strong subscription and advertising income [5] Stock Analysis - VeriSign is identified as one of the overbought stocks with an RSI of 70.45, indicating potential short-term pullback risks despite a target price suggesting over 7% downside [2] - Netflix's average target price is approximately $1,116, indicating only about 1% upside potential from the recent closing price [6] - Bristol-Myers Squibb and UnitedHealth Group are noted as oversold stocks, with RSIs of 24.41 and 28.87 respectively, and both companies have underperformed the market [7] - Bristol-Myers Squibb's stock has dropped over 21.5% in April, while UnitedHealth's has decreased by 20.1% year-to-date [10] Future Outlook - Bristol-Myers Squibb has raised its full-year revenue and earnings guidance, while UnitedHealth has lowered its full-year performance outlook due to rising medical costs [9] - Market consensus target prices suggest over 17% upside potential for Bristol-Myers Squibb and over 36% for UnitedHealth [10]

AirJoule Technologies Corporation (AIRJ) has been on a downward spiral lately with significant selling pressure. After declining 36.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spot ...

Perspective Therapeutics (CATX) has been on a downward spiral lately with significant selling pressure. After declining 16.6% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whe ...

Core Viewpoint - Cassava Sciences, Inc. (SAVA) has experienced a significant downtrend, with a 39.5% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - SAVA's current RSI reading is 24.25, indicating that the heavy selling pressure may be exhausting, which could lead to a price rebound [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding SAVA's earnings potential, with a reported 11.3% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term, supporting the case for a potential turnaround for SAVA [7]. Group 3: Analyst Ratings - SAVA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a near-term turnaround [8].